FDA: New Warning for Procrit, Epogen, Aranesp

New data show that the way Procrit, Epogen, and Aranesp are used in patients with chronic kidney disease puts them at risk of heart attacks, stroke, and death. More conservative dosing is needed.

tennis news tennisnews tennis streams